Fortis Group Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Fortis Group Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$576K	Buy	+4,254	New	+$577K	0.11%	94

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fortis Group Advisors's IBB Position: Q3 2020 in Review

Fortis Group Advisors opened a new position in iShares Biotechnology ETF (IBB) in Q3 2020: 4,254 shares worth $576K. The stake represents 0.11% of the portfolio and ranks #94 among its holdings.

784 funds tracked by Wall St. Rank hold IBB as of Q3 2020.

Fortis Group Advisors held 4,254 shares of iShares Biotechnology ETF worth $576K as of Q3 2020.
iShares Biotechnology ETF was a new Fortis Group Advisors position in Q3 2020.
iShares Biotechnology ETF made up 0.11% of Fortis Group Advisors's portfolio in Q3 2020, its #94 holding.
784 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2020.

Based on Fortis Group Advisors's 13F filing for Q3 2020, filed 17 Nov 2020.